ライフサイエンスコーパス: impaired glucose tolerance

1 17 with impaired fasting glucose and 33 with impaired glucose tolerance).

2 e, insulin sensitive, insulin resistant, and impaired glucose tolerance).

3 reased expression of gluconeogenic genes and impaired glucose tolerance.

4 fication of insulin exocytosis, resulting in impaired glucose tolerance.

5 ce are metabolically less efficient and show impaired glucose tolerance.

6 DIO mice, despite FFA2(-/-) mice displaying impaired glucose tolerance.

7 he metabolic syndrome, including obesity and impaired glucose tolerance.

8 higher fasting glucose levels and moderately impaired glucose tolerance.

9 individuals at high cardiovascular risk with impaired glucose tolerance.

10 mpared with sham, but nonresponders retained impaired glucose tolerance.

11 elevated fasting glucose levels and severely impaired glucose tolerance.

12 nylindol-3-yl)-acrylate (UK5099) resulted in impaired glucose tolerance.

13 levels, and adiposity, along with strikingly impaired glucose tolerance.

14 sponsible for hepatic insulin resistance and impaired glucose tolerance.

15 ident HF hospitalization among patients with impaired glucose tolerance.

16 ent type 2 diabetes in Indian Asian men with impaired glucose tolerance.

17 tors leads to a decreased beta-cell mass and impaired glucose tolerance.

18 e nor female C57BL/6J Slc30a8 KO mice showed impaired glucose tolerance.

19 in patients with impaired fasting glucose or impaired glucose tolerance.

20 blood glucose, decreased plasma insulin, and impaired glucose tolerance.

21 inhibition via an anti-alpha-klotho antibody impaired glucose tolerance.

22 ee text] males treated with PCB-77 exhibited impaired glucose tolerance.

23 n of let-7 results in insulin resistance and impaired glucose tolerance.

24 k of type 2 diabetes mellitus in adults with impaired glucose tolerance.

25 reduced insulin production and secretion and impaired glucose tolerance.

26 2 wk, at which time they developed similarly impaired glucose tolerance.

27 velocity (NCV) and sensory deficits prior to impaired glucose tolerance.

28 ive glucose-stimulated insulin secretion and impaired glucose tolerance.

29 lderly Americans and 30.8 for Americans with impaired glucose tolerance.

30 , which results in systemic inflammation and impaired glucose tolerance.

31 d plasma FFA and insulin concentrations, and impaired glucose tolerance.

32 ed neonatal beta cell expansion and mass and impaired glucose tolerance.

33 ree additional subjects were identified with impaired glucose tolerance.

34 -beta mRNA levels in subjects with normal or impaired glucose tolerance.

35 are prone to greater insulin resistance and impaired glucose tolerance.

36 nts weigh more, are hyperlipidemic, and have impaired glucose tolerance.

37 ncreased risk of diabetes among persons with impaired glucose tolerance.

38 asted and fed mice but paradoxically also in impaired glucose tolerance.

39 the DPP cohort 25 years of age or older with impaired glucose tolerance.

40 ulin secretion in response to glucose and an impaired glucose tolerance.

41 reduce the risk for diabetes in people with impaired glucose tolerance.

42 its prevalence and prevention in those with impaired glucose tolerance.

43 autoantibody-positive at-risk children with impaired glucose tolerance.

44 ns in the human paired box gene PAX6 lead to impaired glucose tolerance.

45 .05), along with a 2-fold higher insulin and impaired glucose tolerance.

46 ffect of systemic insulin administration and impaired glucose tolerance.

47 nsulin secretion led to a high prevalence of impaired glucose tolerance.

48 another 37% have impaired fasting glucose or impaired glucose tolerance.

49 iabetes, two indeterminate glycemia, and six impaired glucose tolerance.

50 participants had impaired fasting glucose or impaired glucose tolerance.

51 s on quadriceps muscles from obese mice with impaired glucose tolerance.

52 Moreover, mCaROCK1 mice also displayed impaired glucose tolerance.

53 ed by the Homeostatic Model Assessment), and impaired glucose tolerance.

54 food intake, reduced energy expenditure, and impaired glucose tolerance.

55 groups, but 65% of participants with CKD had impaired glucose tolerance.

56 e and those with impaired fasting glucose or impaired glucose tolerance.

57 ssociated with an increased adjusted odds of impaired glucose tolerance (1.7; 1.3-2.1), diabetes (2.3

58 levels have previously been associated with impaired glucose tolerance(2), insulin resistance(3) and

59 We analysed data on 749 adults with impaired glucose tolerance (278 men and 471 women, mean

60 The new impaired glucose tolerance 4 (IGT4) model was selected u

61 those without gestational diabetes but with impaired glucose tolerance, a lower carbohydrate intake

62 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a systolic BP treatment goal

63 ese patients with coronary heart disease and impaired glucose tolerance, acarbose did not reduce the

64 (NAVIGATOR), 9306 research participants with impaired glucose tolerance and >/=1 cardiovascular risk

65 de content was 2.3-fold higher in those with impaired glucose tolerance and 2.1-fold higher in those

66 Short sleep duration is associated with impaired glucose tolerance and an increased risk of diab

67 ng cassette transporter A1 (ABCA1) result in impaired glucose tolerance and beta-cell dysfunction.

68 kout mice fail to expand adaptively and show impaired glucose tolerance and beta-cell dysfunction.

69 th control littermates, knockout mice showed impaired glucose tolerance and circulating leptin, GLP-1

70 fusion of a specific PREP inhibitor, S17092, impaired glucose tolerance and decreased insulin levels

71 Cd39/Entpd1-null mice have impaired glucose tolerance and decreased insulin sensiti

72 zard ratios in patients diagnosed with PTDM, impaired glucose tolerance and diabetes before transplan

73 To date, limited data in subjects with impaired glucose tolerance and diabetes demonstrate nerv

74 ructive sleep apnea (OSA) is associated with impaired glucose tolerance and diabetes, it remains uncl

75 een to identify novel mutations resulting in impaired glucose tolerance and diabetes.

76 Simvastatin-treated patients had an impaired glucose tolerance and displayed a decreased ins

77 MS mice showed impaired glucose tolerance and disturbed sleep.

78 Phlebotomy of humans with impaired glucose tolerance and ferritin values in the hi

79 le role for L. rhamnosus in the treatment of impaired glucose tolerance and food intake disorders by

80 tal period, which again correlated with both impaired glucose tolerance and GSIS, although BCM remain

81 k between prediabetic markers, in particular impaired glucose tolerance and insulin resistance, and f

82 ) is, albeit inconsistently, associated with impaired glucose tolerance and insulin resistance.

83 RC-deficient mice have been shown to exhibit impaired glucose tolerance and insulin secretion, but th

84 Mice lacking TrkB.T1 show impaired glucose tolerance and insulin secretion.

85 rning fed glucose levels but showed severely impaired glucose tolerance and insulin secretion.

86 a(2+), and mice lacking this channel exhibit impaired glucose tolerance and insulin secretion.

87 DKO/2 mice, but not DKO/1 mice, also showed impaired glucose tolerance and insulin sensitivity-thoug

88 es the adipocyte PPARg cistrome resulting in impaired glucose tolerance and insulin sensitivity.

89 may have protective role against BW gain and impaired glucose tolerance and lipid metabolism.

90 Impaired glucose tolerance and metabolic syndrome are as

91 Patients with impaired glucose tolerance and new-onset diabetes after

92 n increased risk of weight gain and obesity, impaired glucose tolerance and new-onset diabetes, hyper

93 +/- 8.0), who were healthy other than having impaired glucose tolerance and obesity, were enrolled an

94 NOX4 knockout and NOX4betaKO mice exhibited impaired glucose tolerance and peripheral insulin resist

95 of lifestyle intervention for patients with impaired glucose tolerance and provide further justifica

96 ose-tolerant mice, and prediabetic mice with impaired glucose tolerance and reduced circulating insul

97 overexpression of Let-7 in mice resulted in impaired glucose tolerance and reduced glucose-induced p

98 dult murine pancreatic beta-cells results in impaired glucose tolerance and reduced insulin secretion

99 at these mutant mice displayed significantly impaired glucose tolerance and reduced insulin sensitivi

100 ompetent and immune deficient) with severely impaired glucose tolerance and significant loss of adipo

101 eceptor (NPRC) increased in individuals with impaired glucose tolerance and T2D.

102 cle, leading to postprandial hyperglycaemia, impaired glucose tolerance and T2D.

103 ave been recently reported to be elevated in impaired glucose tolerance and type 2 diabetes mellitus

104 Impaired glucose tolerance and type 2 diabetes were indu

105 In a high-fat diet-fed mouse model of impaired glucose tolerance and type 2 diabetes, dibenzaz

106 obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes.

107 , HbA1c [-10 g/L (95% CI: -12.90, -7.10 g/L; impaired glucose tolerance) and -6 g/L (95% CI: -8.47, -

108 eria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were randomly assigned i

109 by hyperglycaemia in the postprandial state (impaired glucose tolerance) and/or fasting state (impair

110 rweight and obese normoglycemic (obese), (3) impaired glucose tolerance, and (4) type 2 diabetes mell

111 ies typical of T2D, including hyperglycemia, impaired glucose tolerance, and a substantial reduction

112 ine treatment acutely increased food intake, impaired glucose tolerance, and altered physical activit

113 HF mice developed obesity, impaired glucose tolerance, and elevated free fatty acid

114 sted in increased body weight and adiposity, impaired glucose tolerance, and elevated insulin levels.

115 s defined as impaired fasting glucose and/or impaired glucose tolerance, and high CVD risk as 10 year

116 tors for hepatic steatosis were male gender, impaired glucose tolerance, and increased body mass inde

117 a high-fat diet develop increased body fat, impaired glucose tolerance, and insulin resistance in th

118 AGM was defined as impaired fasting glucose, impaired glucose tolerance, and new onset diabetes after

119 circulating levels of undercarboxylated OCN, impaired glucose tolerance, and reduced energy expenditu

120 exposure is associated with higher body fat, impaired glucose tolerance, and reduced insulin secretio

121 ly relevant because humans who have obesity, impaired glucose tolerance, and T2DM reportedly have def

122 ns were persons without diabetes, those with impaired glucose tolerance, and those with type 2 diabet

123 e on screening for impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes in asymp

124 supportive-care group had severe infections, impaired glucose tolerance, and weight gain of more than

125 with established coronary heart disease and impaired glucose tolerance, and whether the incidence of

126 Severe infections, impaired glucose tolerance, and/or weight gain in the fi

127 %) were diabetic while a further 55 (2%) had impaired glucose tolerance; and 218 (7%) were current sm

128 Kcne2 deletion in mice impaired glucose tolerance as early as 5 wk of age in pu

129 expressing PGC-1alpha exhibited at adult age impaired glucose tolerance associated with reduced insul

130 of birth, but reduced insulin secretion and impaired glucose tolerance at 6 months of age.

131 rt focuses on 11,827 men without diabetes or impaired glucose tolerance at entry for whom follow-up g

132 individuals at high cardiovascular risk with impaired glucose tolerance, both baseline levels of dail

133 t mice (MKOs), which developed significantly impaired glucose tolerance but showed normal peripheral

134 in children with beta cell autoimmunity and impaired glucose tolerance, but not in children with ear

135 the onset of type 2 diabetes in people with impaired glucose tolerance, but whether this leads subse

136 islet-specific Senp1 deletion in mice caused impaired glucose tolerance by reducing the amplification

137 tervention programme for Chinese people with impaired glucose tolerance can reduce incidence of cardi

138 se patients with type 2 diabetes mellitus or impaired glucose tolerance, canakinumab had no effect co

139 rolimus, sirolimus, and tacrolimus/sirolimus impaired glucose tolerance compared to control.

140 ght, adipose mass, adipose inflammation, and impaired glucose tolerance compared with AhR(fl/fl) cont

141 G6PD-deficient mice had smaller islets and impaired glucose tolerance compared with control mice, w

142 to-d-serine ratios were lower in humans with impaired glucose tolerance compared with normal glucose

143 edentary dams produced female offspring with impaired glucose tolerance compared with offspring of ch

144 posity as early as 2 weeks of age as well as impaired glucose tolerance compared with offspring of da

145 results in compromised insulin secretion and impaired glucose tolerance compared with WT mice.

146 mice, resulted in decreased beta cell mass, impaired glucose tolerance, defective insulin secretion,

147 Lifestyle intervention in people with impaired glucose tolerance delayed the onset of type 2 d

148 rbances, including increased meal frequency, impaired glucose tolerance, delayed gastric emptying, an

149 throughout the developing pancreas leads to impaired glucose tolerance, deletion in the beta cell in

150 Indeed, both hyperinsulinemia and impaired glucose tolerance developed spontaneously betwe

151 h-fat diet (HFD), body weight (BW) gain, and impaired glucose tolerance development are associated wi

152 ated in their pancreatic pericytes exhibited impaired glucose tolerance due to compromised beta-cell

153 n of CaMKII in beta-cells show significantly impaired glucose tolerance due to decreased GSIS.

154 hat PCB-77 administration to obese male mice impaired glucose tolerance during weight loss.

155 lly identifiable in the prediabetic phase of impaired glucose tolerance, early intervention might pre

156 beta-cell human IAPP (hIAPP) expression had impaired glucose tolerance, elevated islet Il1b mRNA, an

157 dysfunction in patients with prediabetes or impaired glucose tolerance emphasizes the susceptibility

158 ences, knock-out mice showed a significantly impaired glucose tolerance following oral and intraperit

159 ressive hyperglycemia, hyperinsulinemia, and impaired glucose tolerance from 12 weeks of age without

160 28%, whereas HbA1c detected NODAT in 10% and impaired glucose tolerance (from >/=5.7 to <6.5%) in 51%

161 Impaired glucose tolerance, gestational diabetes, and hy

162 re reduced (P < 0.01) during the OGTT in the impaired glucose tolerance groups, indicating that reduc

163 D displayed lower plasma insulin level, less impaired glucose tolerance (GT), and higher plasma T3 co

164 islet expansion and led to hyperglycemia and impaired glucose tolerance, hallmark features of gestati

165 Some patients with impaired glucose tolerance have a reversal of neuropathi

166 metabolic disease, including hyperglycemia, impaired glucose tolerance, hyperinsulinemia, hepatic st

167 haracterized by obesity, insulin resistance, impaired glucose tolerance, hyperlipidemia, and cardiova

168 t diet resulted in greater fat accumulation, impaired glucose tolerance, hyperlipidemia, increased se

169 However, pups weaned onto high-fat diet had impaired glucose tolerance if their dams were on a high-

170 tudy that overweight and obese subjects with impaired glucose tolerance (IGT(+)) display significant

171 type 2 diabetes (n = 145) or type 2 diabetes/impaired glucose tolerance (IGT) (n = 293) with those of

172 We identified impaired glucose tolerance (IGT) and gestational diabete

173 sformed and categorized into quartiles) with impaired glucose tolerance (IGT) and gestational diabete

174 n was lower (P < 0.001) in subjects with IFG/impaired glucose tolerance (IGT) and IFG/diabetes but di

175 Type 2 diabetes is characterized by impaired glucose tolerance (IGT) and insulin resistance

176 ing glucose (IFG) and compare the results to impaired glucose tolerance (IGT) and normal glucose tole

177 ysfunction is central to the pathogenesis of impaired glucose tolerance (IGT) and type 2 diabetes.

178 Aging increases the risk of developing impaired glucose tolerance (IGT) and type 2 diabetes.

179 ated with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from published prospect

180 Subjects with impaired glucose tolerance (IGT) have increased myocardi

181 Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) identify individuals at

182 nsulin resistance (IR) and inflammation, and impaired glucose tolerance (IGT) in the prediction of DM

183 rdiac dietary fatty acid (DFA) metabolism in impaired glucose tolerance (IGT) is different in men and

184 g glucose (IFG) is more prevalent in men and impaired glucose tolerance (IGT) more prevalent in women

185 Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) often coexist and as su

186 ch were determined; and 32 participants with impaired glucose tolerance (IGT) or diet-controlled type

187 miscategorize up to 40% of individuals with impaired glucose tolerance (IGT) or frank diabetes based

188 development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participat

189 ts are also associated with progression from impaired glucose tolerance (IGT) to diabetes and respons

190 disposition index [DI]) in obese youth with impaired glucose tolerance (IGT) versus normal glucose t

191 generation) develop progressive obesity and impaired glucose tolerance (IGT) with aging.

192 lin-sensitive subjects, 10 participants with impaired glucose tolerance (IGT), 11 with T2D, and 8 hea

193 management of renal transplant patients with impaired glucose tolerance (IGT), a risk factor for the

194 sts in identifying impaired fasting glucose, impaired glucose tolerance (IGT), and NODAT.

195 tance without carbohydrate intolerance (IR), impaired glucose tolerance (IGT), and normotensive and h

196 -IR]) in a large group of subjects with NGT, impaired glucose tolerance (IGT), and T2DM.

197 ng to the development of insulin resistance, impaired glucose tolerance (IGT), and type 2 diabetes ar

198 ubjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes, u

199 humans with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or T2DM.

200 diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), potentially resulting

201 puberty timing and type 2 diabetes (T2D) or impaired glucose tolerance (IGT), with and without adjus

202 as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).

203 tivity associated with future development of impaired glucose tolerance (IGT).

204 e prevented with intervention in people with impaired glucose tolerance (IGT).

205 antation (NODAT) and ignore the diagnosis of impaired glucose tolerance (IGT).

206 s with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT).

207 lucagon levels are observed in subjects with impaired glucose tolerance (IGT).

208 ish subjects with type 2 diabetes (n = 137), impaired glucose tolerance (IGT; n = 139), and normal gl

209 TS [normal glucose tolerance (NGT; n = 190), impaired glucose tolerance (IGT; n = 209), and diabetes

210 with normal glucose tolerance [NGT], 57 with impaired glucose tolerance [IGT], and 207 with type 2 di

211 with normal glucose tolerance [NGT], 48 with impaired glucose tolerance [IGT], and 34 with type 2 dia

212 es (normal glucose tolerance [NGT], n = 712; impaired glucose tolerance [IGT], n = 353; newly diagnos

213 ) subjects classified as glucose intolerant (impaired glucose tolerance [IGT]; n = 17) or treatment-n

214 The ghrelin agonist impaired glucose tolerance immediately after administrat

215 Hyperglycemia, be it secondary to diabetes, impaired glucose tolerance, impaired fasting glucose, or

216 2-month data, OGTT recorded NODAT in 14% and impaired glucose tolerance in 28%, whereas HbA1c detecte

217 The findings indicate a role of H. pylori in impaired glucose tolerance in adults that may be potenti

218 an insulin secretory defect, which exhibits impaired glucose tolerance in association with insulin r

219 Impaired glucose tolerance in betaLPL-KO mice was presen

220 Ritonavir impaired glucose tolerance in control mice but did not e

221 rolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) C

222 found that genetic deletion of A2AARs caused impaired glucose tolerance in mice fed an HFD.

223 antimiR was sufficient to prevent and treat impaired glucose tolerance in mice with diet-induced obe

224 Obesity significantly increases risk of impaired glucose tolerance in pregnancy, but glycemic ef

225 R blockade with the antagonist exendin(9-39) impaired glucose tolerance in WT mice but had no effect

226 gh-fat feeding of sedentary dams resulted in impaired glucose tolerance, increased serum insulin conc

227 s, respectively (both P<0.0001), manifesting impaired glucose tolerance, insulin resistance, and card

228 In humans, impaired glucose tolerance is accompanied by cardiac ste

229 Impaired glucose tolerance is associated with HI, althou

230 Impaired glucose tolerance is associated with increased

231 ect of these interventions on people without impaired glucose tolerance is lacking.

232 carbohydrate during pregnancy combined with impaired glucose tolerance is postulated to result in hi

233 in patients with coronary heart disease and impaired glucose tolerance is unknown.

234 Abnormal glucose tolerance (AGT; diabetes or impaired glucose tolerance) is associated with increased

235 mean difference 0.30 [95% CI 0.18 to 0.42]), impaired glucose tolerance (mean difference 1.31 [0.37 t

236 ish subjects with type 2 diabetes (n = 145), impaired glucose tolerance (n = 148), and normal glucose

237 7 to 2.25]), and the number of patients with impaired glucose tolerance (odds ratio 5.44 [2.63 to 11.

238 During weight loss, PCB-77 impaired glucose tolerance of males.

239 ts of lifestyle interventions in people with impaired glucose tolerance on the incidence of diabetes,

240 In contrast, POMC-Shp2-/- mice displayed impaired glucose tolerance only secondary to their incre

241 tment might also be useful for patients with impaired glucose tolerance or diabetes.

242 8) met criteria for impaired fasting glucose/impaired glucose tolerance or diabetes.

243 accompanied by systemic insulin resistance; impaired glucose tolerance or diabetes; islet beta cell

244 n oral glucose tolerance test, 196 (15%) had impaired glucose tolerance or impaired fasting glucose a

245 n men or 80 cm or greater in women, and with impaired glucose tolerance or impaired fasting glucose d

246 onset of cardiomyopathy in individuals with impaired glucose tolerance or in patients with type 2 di

247 We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver

248 Among patients with impaired glucose tolerance or type 2 diabetes, rosiglita

249 e liver (eight subjects) in adolescents with impaired glucose tolerance or type 2 diabetes.

250 efit to individuals, particularly those with impaired glucose tolerance or type 2 diabetes.

251 e individuals with impaired fasting glucose, impaired glucose tolerance, or both [22 women, 17 men; m

252 lar events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g

253 glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or diabetes.

254 ned clinically normal without hyperglycemia, impaired glucose tolerance, or hepatic glycogen depletio

255 insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in no

256 risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receiv

257 In Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR)

258 In humans with impaired glucose tolerance, PPARgamma agonist treatment

259 surgical patients and from 38 subjects with impaired glucose tolerance randomized to receive either

260 Lifestyle interventions among people with impaired glucose tolerance reduce the incidence of diabe

261 k and Bmal1 (also called Arntl) mutants show impaired glucose tolerance, reduced insulin secretion an

262 However, studies of women with impaired glucose tolerance show that replacing refined c

263 lin receptor in BAT transplant mice leads to impaired glucose tolerance, similar to what is seen in n

264 cortical metabolism, as well as chronically impaired glucose tolerance, suggest that disturbed neuro

265 ko mice exhibited fasting hyperglycemia and impaired glucose tolerance test compared with wild-type

266 flammasome activity in aged mice resulted in impaired glucose tolerance that could be attributed to p

267 iabetes mellitus or impaired fasting glucose/impaired glucose tolerance that enrolled at least 100 pa

268 Among research participants with impaired glucose tolerance, there are several easily ide

269 46 were more likely to have progression from impaired glucose tolerance to diabetes than were CC homo

270 the progression of patients from a state of impaired glucose tolerance to full blown type 2 diabetes

271 eta cell failure underlies the transition of impaired glucose tolerance to overt diabetes; endoplasmi

272 P) recruited and randomized individuals with impaired glucose tolerance to treatment with placebo, me

273 oglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus b

274 glucose/lipid metabolism in 47 patients with impaired glucose tolerance/type 2 diabetes mellitus and

275 s also have higher plasma insulin levels and impaired glucose tolerance upon HFD feeding, relative to

276 enous estrogen, or hypertension therapy; and impaired glucose tolerance), waist circumference, homeos

277 This impaired glucose tolerance was caused by a decrease in i

278 Impaired glucose tolerance was not a prerequisite for th

279 g the first year after renal transplantation.Impaired glucose tolerance was not associated with eithe

280 TB disease progression in guinea pigs with impaired glucose tolerance was similar to that of nondia

281 glucose-tolerant subjects, individuals with impaired glucose tolerance were more insulin resistant,

282 Decreased bodyweight and impaired glucose tolerance were observed as were reduced

283 sease and either type 2 diabetes mellitus or impaired glucose tolerance were randomized to receive pl

284 Working Indian men (aged 35-55 years) with impaired glucose tolerance were randomly assigned (1:1)

285 ese patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1),

286 cs in Da Qing, China-serving 577 adults with impaired glucose tolerance-were randomised (1:1:1:1) to

287 +/- mice, but not BALB/cJ Npc1+/- mice, have impaired glucose tolerance when fed a low-fat diet and i

288 up of patients with CF with normal to mildly impaired glucose tolerance, whereas incretin secretion r

289 iomyopathy in TG9 animals was accompanied by impaired glucose tolerance, which was acutely exacerbate

290 oping gestational diabetes mellitus and have impaired glucose tolerance whilst cholestatic.

291 tion on long-term outcomes among adults with impaired glucose tolerance who participated in the Da Qi

292 us exercise) for 6 years for 577 adults with impaired glucose tolerance who usually receive their med

293 the progression to diabetes in persons with impaired glucose tolerance who were enrolled in the Diab

294 IGATOR trial involving 9306 individuals with impaired glucose tolerance who were recruited in 40 coun

295 approaches that better identify people with impaired glucose tolerance, who benefit from the current

296 evention Program, treatment of subjects with impaired glucose tolerance with metformin >3.2 years red

297 geted using respective Cre mice: reversible, impaired glucose tolerance with normoglycemia in pancrea

298 ion, we used ABCA1(-l/-l) mice, which showed impaired glucose tolerance without changes in insulin se

299 Participants had impaired glucose tolerance (World Health Organization cr

300 ening test and reserving OGTT for those with impaired glucose tolerance would detect NODAT with a sen